Wednesday, 26 August 2026European Markets

CASINO GUICHARD Stock Is 29% Down In The Last 21 Sessions

Loading stream...

(vianews) - shares of casino guichard (cac 40: co.pa) dropped by a staggering 29.19% in 21 sessions from €8.6 to €6.09 at 02:54 est on monday, following the last session's upward trend. cac 40 is rising 0.12% to €7,324.75, following the last session's upward trend.

casino guichard's last close was €6.09, 68.4% under its 52-week high of €19.27.

about casino guichard

casino, guichard-perrachon s.a. operates as a food retailer in france, latin america, and internationally. the company operates hypermarkets, supermarkets, shopping malls, and e-commerce sites, as well as convenience, discount, and cash and carry stores. it also involved in banking, digital marketing, service station, franchise, real estate asset management, property development and trading, rental, banking, and energy-related activities. it operates through stores. the company was founded in 1898 and is based in saint-étienne, france.

earnings per share

as for profitability, casino guichard has a trailing twelve months eps of €-8.54.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -5.53%.

revenue growth

year-on-year quarterly revenue growth grew by 9.3%, now sitting on 34b for the twelve trailing months.

more news about casino guichard (co.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com